API Holdings Limited (PharmEasy) Unlisted Shares

API Holdings Limited (PharmEasy) Company Overview:

API Holdings Limited is the largest digital healthcare platform (based on GMV of products and services sold for the year ended March 31, 2021) which through custom-built technology platform and supply chain capabilities, operates an integrated and end-to-end interconnected network business serving the healthcare needs of stakeholders.

Progress till now:

The founders started Dialhealth, a consumer pharmaceutical delivery service in Mumbai where they realized the supply chain issues. As a result, they founded ascent in 2013 which distributed pharma products to pharmacies where they built strong supply chain capabilities. After building strong supply chain capabilities in 2015, founders built a pharmeasy marketplace. They acquired docon in 2016 which provides EMR and clinic management service along with teleconsultation offerings. The company built retailio to accelerate technology adoption and to expand supply chain capabilities beyond pharmacies. In 2020, all businesses were consolidated into API holdings to create an integrated digital healthcare platform. In 2021, they acquired medlife, aknamed, and thyrocare. They also acquired a 49% stake in Marg.

With these acquisitions, the company now touches every stakeholder involved in healthcare – consumers, doctors, laboratories, and hospitals.

Key Milestones as per report of 2024 are as under:

The key milestones were:
• The Company increased the number of labs accredited by the National Accreditation
Board for Testing and Calibration Laboratories (“NABL”) from 15 to 25.
• In March 2024, approximately 95% of total samples were processed in NABLaccredited labs.
• The Company conducted around 147 million tests, representing a 4% year-on-year
growth.
• For the purpose of these tests, around 22 million samples were processed, indicating
an 8% year-on-year growth in samples processing.
• The Company’s active franchisee base increased to over 7,900, more than doubled in
the last three years.
Marketplace to avail diagnostics services offered by our brand PharmEasy Labs.
PharmEasy Labs recorded revenues of INR 1,164.76 million in Fiscal 2024.

Other services including fulfilment (services to customer for pharmaceutical and OTC
products sold on PharmEasy marketplace) and technology services, software services for
doctors and pharmacies and Retailio technology generated revenue of INR 433.28 million
in Fiscal 2024.
Retailio provides technology which enables wholesalers and pharmacies to connect and
sell a wide range of pharma and other medical products. It is available as a mobile app
and web application. For the month of March 2024, 109,028 pharmacies and 3,272
wholesalers used Retailio to fulfil their procurement needs.

Board of directors of the company:

Name	Designation
Mr. Siddharth Shah	MD & CEO
Mr. Aditya Puri	Chairman and Non-executive director
Dr. Dhaval Shah	Whole-time director
Mr. Hardik Dedhia	Whole-time director
Mr. Ashutosh Sharma	Non-executive director
Mr. Ankur Thadani	Non-executive director
Mr. Deepak Vaidya	Independent, Non-Executive Director
Ms. Vineeta Rai	Independent, Non-Executive Director
Mr. Subramaniam Somasundaram	Independent, Non-Executive Director
Mr shyam Powar	Non- executive Director
Dovaldas Buzinskas	Non-executive director
Mr. Jaydeep Tank	Independent director

Past performance of the company:

(All figures INR in crores except EPS data)

The company issued 10 bonus shares for every share held on 28^th October 2021 and also sub-divided equity shares from FV 10 to FV 1.

Particulars of the company	2024	2023
Total Revenue	5,664.29	6,643.94
Profit before Tax (PBT)	-2,521.20	-5,196.52
Profit After Tax (PAT)	-2,531.17	-5,202.57
Earnings per share (EPS) (INR)	-4.07	-8.51

API Holdings Limited 2024

API-Holdings-Limited-2024.pdf

Company details:

Particulars	Details
Face Value	1
ISIN	INE0DJ201029
PAN Number	AASCA1201E

API Holdings Limited in the news:

PharmEasy Rights Issue: Epharmacy Raises INR 1,804 Cr At A 90% Valuation Cut:
Exclusive | Aditya Puri joins board of PharmEasy’s parent API Holdings ahead of IPO: https://www.moneycontrol.com/news/business/exclusive-aditya-puri-joins-board-of-pharmeasys-parent-api-holdings-ahead-of-ipo-6977151.html

Frequently Asked Questions (FAQs) on API Holdings Limited (PharmEasy) Unlisted Shares:

1. How to buy API Holdings Limited (PharmEasy) Unlisted Shares:

The step-by-step process for buying API Holdings Limited (PharmEasy) at current Share Price in unlisted Market is as follows:

Step 1:A deal is reached between us and buyer either on WhatsApp or over email.
Step 2:Buyer transfers deal amount to bank account details provided by us and provide us below documents:
1. Remitter name, account number, bank name and UTR no. for the amount transferred to us.
2. Client master copy of the remitter. The shares will be transferred to details provided in the client master copy.
3. PAN card
Step 3:We shall transfer shares to buyer account on the same day of receipt of funds and raise contract note for the same.

Diagram showing how to buy shares is as below:

See the Infographic flow to buy the shares

2. How to sell API Holdings Limited (PharmEasy) Unlisted Shares:

Step by step process to sell Unlisted shares of API Holdings Limited (PharmEasy) Unlisted Shares is as under:

Step 1:A deal is reached between us and seller either on WhatsApp or over email.
Step 2:Seller transfer shares to unlisteddeal.com’s dp details provided to them and provide their PAN card and beneficiary bank details
Step 3:We shall remit the funds (make the payment) to the seller on the same day of receipt of shares.

Diagram showing how to sell shares is as below:

See the Infographic flow to sell the shares